Moderna's US stock rose more than 30% before the market, and the company and MSD announced that the melanoma skin cancer vaccine had reached the target impact in large-scale trials.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.